Spinal Muscular Atrophy News and Research

RSS
Spinal muscular atrophy (SMA) is a motor neuron disease and the leading genetic cause of death among infants and toddlers. Characterized by selective loss of nerve cells in the spinal cord, the disease leads to increasing muscular weakness and atrophy. Over time, patients afflicted by SMA continue to lose muscle control and strength, leading to progressive inability to walk, stand, sit up and breathe. It is estimated that approximately 1 in 6,000 to 1 in 10,000 infants are born annually worldwide with SMA.
Cedars-Sinai receives California Institute grant to develop new technique for specific diseases

Cedars-Sinai receives California Institute grant to develop new technique for specific diseases

RBM, SMA Foundation collaborate to develop plasma protein biomarkers for spinal muscular atrophy

RBM, SMA Foundation collaborate to develop plasma protein biomarkers for spinal muscular atrophy

MDA awards Repligen $1.4M for research of new compound with therapeutic potential for SMA

MDA awards Repligen $1.4M for research of new compound with therapeutic potential for SMA

MDA commits to invest funds in FSMA Quinazoline Program

MDA commits to invest funds in FSMA Quinazoline Program

MDA supports Repligen with $1.4M grant for RG3039 Spinal Muscular Atrophy development program

MDA supports Repligen with $1.4M grant for RG3039 Spinal Muscular Atrophy development program

CSC files IND application to commence Phase I study for Spinal Muscular Atrophy

CSC files IND application to commence Phase I study for Spinal Muscular Atrophy

Comprehensive guide to current practice of intraoperative neurophysiology

Comprehensive guide to current practice of intraoperative neurophysiology

PROTOX closes first tranche of investment by Warburg Pincus

PROTOX closes first tranche of investment by Warburg Pincus

New computational techniques to overcome obstacles in hard-to-study genes

New computational techniques to overcome obstacles in hard-to-study genes

Critical piece of puzzle in treatment of Spinal Muscular Atrophy

Critical piece of puzzle in treatment of Spinal Muscular Atrophy

SMA researchers receive grant for Spinal Muscular Atrophy research

SMA researchers receive grant for Spinal Muscular Atrophy research

iPierian raises $28 million from Series B equity financing closure

iPierian raises $28 million from Series B equity financing closure

Research on motor neuron subtype may provide useful therapy for neuron diseases

Research on motor neuron subtype may provide useful therapy for neuron diseases

Study finds genetic change in chromosome 4 causes FSHD

Study finds genetic change in chromosome 4 causes FSHD

Muscular Dystrophy Association awards $14.1M in new grants

Muscular Dystrophy Association awards $14.1M in new grants

MDA awards $14.1 million in new grants to advance treatments and cures for muscle diseases

MDA awards $14.1 million in new grants to advance treatments and cures for muscle diseases

Dr. Hastings receives grant for Spinal Muscular Atrophy research

Dr. Hastings receives grant for Spinal Muscular Atrophy research

Spinal muscular atrophy may lead to cardiac dysfunction: Study

Spinal muscular atrophy may lead to cardiac dysfunction: Study

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Long-term exposure to valproate leads to bone loss: Study

Long-term exposure to valproate leads to bone loss: Study